| |
 |
|
 |
|
上海復旦張江生物醫藥股份有限公司 |
股票代號: |
01349 |
| SHANGHAI FUDAN-ZHANGJIANG BIO-PHARMACEUTICAL CO. LTD. |
集團網址： |
http://www.fd-zj.com |
| 損益表 |
| |
2025/12
RMB($) |
變動 |
2024/12
RMB($) |
2023/12
RMB($) |
| 營業額 | 685,797,316 | -3.328% | 709,404,966 | 850,733,212 | | 經營溢利/(虧損) | (130,755,861) | -- | 34,011,168 | 121,067,590 | | 特殊項目 | -- | -- | -- | -- | | 攤佔聯營公司及共同控制公司溢利/(虧損) | (25,095,447) | -- | (28,553,238) | (23,539,527) | | 稅前溢利/(虧損) | (155,851,308) | -- | 5,457,930 | 97,528,063 | | 稅項 | (1,872,270) | -- | 33,976,142 | 10,921,795 | | 少數股東權益 | 284,080 | -5.251% | 299,824 | 177,510 | | 股東應佔溢利/(虧損) | (157,439,498) | -- | 39,733,896 | 108,627,368 | | | | 淨利息收入/(支出) | 2,146,606 | -56.697% | 4,957,190 | 4,906,185 | | 折舊與攤銷 | 78,651,761 | -4.340% | 82,219,826 | 62,232,225 | | 董事酬金 | 3,834,450 | -1.773% | 3,903,670 | 4,915,650 | | | | 每股盈利/(虧損)(仙) | (15.000) | -- | 4.000 | 11.000 | | 每股派息(仙) | 0.000 | -- | 5.000 | 7.000 | | | | 派息比率(％) | -- | -- | 125.000% | 63.636% | | 每股帳面資產淨值($) | 2.042 | -8.170% | 2.223 | 2.274 |
|
| 主要財務比率 |
| |
2025/12
RMB($) |
變動 |
2024/12
RMB($) |
2023/12
RMB($) |
| 經營邊際利潤率(％) | (19.066)% | -- | 4.794% | 14.231% | | 利息盈利率(x) | -- | -- | 10.225 | 32.807 | | 資產回報率(％) | (6.326)% | -- | 1.455% | 3.712% | | 股東資金回報率(％) | (7.123)% | -- | 1.705% | 4.708% | |
|
|
|
|
|
|
 |
Copyright © 2026 ET Net Limited.
All rights reserved. Use of this site signifies your agreement to the terms of use.
DISCLAIMER: ET Net Limited and Third Party Information Providers endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
|
|
|